This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Delea T, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge HJ, Walker MD.Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who received prior therapy with trastuzumab based on updated survival data from EGF100151. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 6559, 30 May 2008. Available from: URL: http://www.asco.org
Le QA, Hay J.Cost-utility analysis of lapatinib in treatment of HER2-positive advanced breast cancer. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 6553, 30 May 2008. Available from: URL: http://www.asco.org
Benedict A, Charbonneau C, Hidi J, Kim ST, Négrier S.Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon-alfa or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma: an indirect comparison. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 5048, 30 May 2008. Available from: URL: http://www.asco.org
Horgan AM, Shepherd FA, Bradbury PA, Ng R, Leighl NB.Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 8110, 30 May 2008. Available from: URL: http://www.asco.org
Safont M, Darba J, Restovic G, Sastre J, Bellmunt Molins J, Gomez MA, Salgado M, Vila C, Ramirez de Arellano A.Economic assessment of capecitabine/cisplatin versus 5-FU/cisplatin regimens in adjuvant treatment of advanced gastric cancer in Spain. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 15549, 30 May 2008. Available from: URL: http://www.asco.org
Chang C, Chao Y, Chen J, Chen L, Chuang C, Hsieh R, Hwang W, Yang L, de Reydet F.Pharmacoeconomic analysis of capecitabine for advanced gastric cancer in Taiwan. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 15576, 30 May 2008. Available from: URL: http://www.asco.org
Rights and permissions
About this article
Cite this article
News from ASCO. Pharmacoecon. Outcomes News 555, 8–9 (2008). https://doi.org/10.2165/00151234-200805550-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805550-00014